<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prothrombin complex concentrate, 4-factor, unactivated, from human plasma: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prothrombin complex concentrate, 4-factor, unactivated, from human plasma: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Prothrombin complex concentrate, 4-factor, unactivated, from human plasma: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12048" href="/d/html/12048.html" rel="external">see "Prothrombin complex concentrate, 4-factor, unactivated, from human plasma: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F20858539"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Arterial and venous thromboembolic complications:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients being treated with vitamin K antagonist therapy have underlying disease states that predispose them to thromboembolic events. Potential benefits of reversing vitamin K antagonists should be weighed against the potential risks of thromboembolic events, especially in patients with history of a thromboembolic event. Resumption of anticoagulation should be carefully considered as soon as the risk of thromboembolic events outweighs the risk of acute bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Both fatal and nonfatal arterial and venous thromboembolic complications have been reported with prothrombin complex concentrate in clinical trials and postmarketing surveillance. Monitor patients receiving prothrombin complex concentrate for signs and symptoms of thromboembolic events.</p>
<p style="text-indent:-2em;margin-left:2em;">Prothrombin complex concentrate was not studied in subjects who had a thromboembolic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectoris, or severe peripheral vascular disease within the prior 3 months. Prothrombin complex concentrate may not be suitable in patients with thromboembolic events in the prior 3 months.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F20858540"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Balfaxar;</li>
<li>Kcentra</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868921"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Beriplex P/N;</li>
<li>Octaplex</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F5541095"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Blood Product Derivative;</li>
<li>
                        Hemostatic Agent;</li>
<li>
                        Prothrombin Complex Concentrate (PCC)</li></ul></div>
<div class="block doa drugH1Div" id="F5541713"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: Prothrombin complex concentrate (human) [(factors II, VII, IX, X), protein C, protein S] contains therapeutic levels of factor VII component</b> and should not be confused with factor IX complex (human) [factors II, IX, X] (Bebulin, Profilnine).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aed8585d-7857-4a4a-8287-c968539855bd">Life-threatening hemorrhage associated with direct factor Xa inhibitor or direct thrombin inhibitor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Life-threatening hemorrhage associated with direct factor Xa inhibitor or direct thrombin inhibitor (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Used for life-threatening bleeding or bleeding into a critical organ that is not controlled with maximal supportive measures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32680646','lexi-content-ref-31732375','lexi-content-ref-30916798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32680646','lexi-content-ref-31732375','lexi-content-ref-30916798'])">Ref</a></span>). Dosage is expressed in units of factor IX activity and based on Kcentra studies.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral direct factor Xa inhibitor mediated (apixaban, betrixaban, edoxaban, rivaroxaban [if andexanet alfa unavailable]): <b>IV:</b> 2,000 units once <b>or</b> 25 to 50 units/kg once, in addition to other supportive measures as clinically indicated (eg, activated charcoal, antifibrinolytic agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32680646','lexi-content-ref-31732375','lexi-content-ref-30916798','lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32680646','lexi-content-ref-31732375','lexi-content-ref-30916798','lexi-content-ref-26714677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Direct thrombin inhibitor mediated (argatroban, dabigatran, bivalirudin [if idarucizumab or activated prothrombin complex concentrate unavailable]): <b>IV:</b> 50 units/kg in addition to other supportive measures as clinically indicated (eg, activated charcoal, hemodialysis, antifibrinolytic agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32680646','lexi-content-ref-31732375','lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32680646','lexi-content-ref-31732375','lexi-content-ref-26714677'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="526070ec-e228-4ccc-86e4-b08d5060004c">Perioperative coagulopathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Perioperative coagulopathy (off label use): Note:</b> Limited data available; also refer to institutional protocols. Dosage is expressed in units of factor IX activity and based on Kcentra studies.</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiac surgery (cardiopulmonary bypass-induced coagulopathy): <b>IV: </b>15 units/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25822921','lexi-content-ref-35767271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25822921','lexi-content-ref-35767271'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiac transplantation: Dosing based on preoperative INR (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37080658','lexi-content-ref-27558534','lexi-content-ref-29397934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37080658','lexi-content-ref-27558534','lexi-content-ref-29397934'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">INR &lt;4:<b> IV:</b> 25 units/kg (maximum dose: 2,500 units).</p>
<p style="text-indent:-2em;margin-left:6em;">INR 4 to 6:<b> IV:</b> 35 units/kg (maximum dose: 3,500 units).</p>
<p style="text-indent:-2em;margin-left:6em;">INR &gt;6:<b> IV:</b> 50 units/kg (maximum dose: 5,000 units).</p>
<p style="text-indent:-2em;margin-left:4em;">Liver transplantation: <b>IV: </b>25 to 40 units/kg as a single dose; higher dose guided by rotational thromboelastometry and/or laboratory values (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24827116','lexi-content-ref-32118854']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24827116','lexi-content-ref-32118854'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Coagulopathy following trauma<b>:</b>
<b>IV:</b> 25 units/kg as a single dose (in combination with fresh frozen plasma) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25886249','lexi-content-ref-27875491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25886249','lexi-content-ref-27875491'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ac4d6317-ca5a-442e-9eed-b7be0dfe133e">Reversal of oral direct factor Xa inhibitor in patients who require urgent procedure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of oral direct factor Xa inhibitor in patients who require urgent procedure (if andexanet alfa unavailable) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reversal agent should be administered only if the procedure cannot safely be performed while the patient is anticoagulated or cannot be delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30916798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30916798'])">Ref</a></span>). Dosage is expressed in units of factor IX activity and based on Kcentra studies.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2,000 units once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30916798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30916798'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="558e622f-b680-400e-9337-88c8fca899ea">Reversal of vitamin K antagonist in patients with acute major bleeding or need for an urgent surgery/invasive procedure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of vitamin K antagonist in patients with acute major bleeding or need for an urgent surgery/invasive procedure:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Individualize dosing based on severity of disorder, INR, extent and location of bleeding, and clinical status of patient. Repeat dosing with prothrombin complex concentrate is usually not necessary when given in combination with vitamin K. Dosage is expressed in units of factor IX activity. Balfaxar is only indicated for reversal of vitamin K antagonist in patients with need for an urgent surgery/invasive procedure. Kcentra, Beriplex P/N [Canadian product], and Octaplex [Canadian product] are indicated for reversal of vitamin K antagonist in patients with acute major bleeding <b>or</b> need for an urgent surgery/invasive procedure<b>.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Balfaxar, Kcentra, Beriplex P/N [Canadian product]:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Weight-based dose:</p>
<p style="text-indent:-2em;margin-left:8em;">Pretreatment INR: 2 to &lt;4: <b>IV: </b>Administer 25 units/kg; maximum dose: 2,500 units.</p>
<p style="text-indent:-2em;margin-left:8em;">Pretreatment INR: 4 to 6: <b>IV: </b>Administer 35 units/kg; maximum dose: 3,500 units.</p>
<p style="text-indent:-2em;margin-left:8em;">Pretreatment INR: &gt;6: <b>IV: </b>Administer 50 units/kg; maximum dose: 5,000 units.</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dose: <b>Note:</b> Dosing based on Kcentra studies.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> Initial: 1,000 to 2,000 units once; for intracranial hemorrhage use, 1,500 to 2,000 units is recommended; repeat dosing has not been adequately studied and is not typically recommended unless INR reversal is inadequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32680646','lexi-content-ref-31787372','lexi-content-ref-31707622','lexi-content-ref-31864879','lexi-content-ref-22491734','lexi-content-ref-30892733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32680646','lexi-content-ref-31787372','lexi-content-ref-31707622','lexi-content-ref-31864879','lexi-content-ref-22491734','lexi-content-ref-30892733'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Octaplex [Canadian product</i>
<i>]:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Pretreatment INR: 2 to 2.5: <b>IV:</b> 22.5 to 32.5 units/kg; maximum dose: 3,000 units (or 120 mL).</p>
<p style="text-indent:-2em;margin-left:6em;">Pretreatment INR: 2.5 to 3: <b>IV:</b> 32.5 to 40 units/kg; maximum dose: 3,000 units (or 120 mL).</p>
<p style="text-indent:-2em;margin-left:6em;">Pretreatment INR: 3 to 3.5: <b>IV: </b>40 to 47.5 units/kg; maximum dose: 3,000 units (or 120 mL).</p>
<p style="text-indent:-2em;margin-left:6em;">Pretreatment INR: &gt;3.5: <b>IV: </b>&gt;47.5 units/kg; maximum dose: 3,000 units (or 120 mL).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991318"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50988661"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doo drugH1Div" id="F20858546"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, or 3 obesity (BMI ≥30 kg/m<sup>2</sup>): IV:</b> For patients ≤100 kg, use <b>actual body weight</b> for weight-based dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). For patients &gt;100 kg, use a maximum 100 <b>kg</b> for dosing weight. Refer to adult dosing for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rationale for recommendations:</b> There is a lack of studies evaluating the influence of obesity on prothrombin complex concentrate (human) dosing or pharmacokinetics. The pharmacokinetics in healthy subjects without obesity is complicated with different included clotting factors having vastly different half-lives. Observational data support use of actual body weight (with a dose cap strategy) as the preferred weight metric in patients with a BMI ≥30 kg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30460443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30460443'])">Ref</a></span>). A retrospective, multi-center study evaluated ≤100 kg and &gt;100 kg cohorts in patients receiving warfarin who received prothrombin complex concentrate for elevated INR and life-threatening bleed or required emergent surgery. This study did not show any difference in normalization of INR or thrombosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34870070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34870070'])">Ref</a></span>). Some retrospective studies have evaluated fixed dosing for vitamin K antagonist reversal; however, there are limited data describing fixed-dosing strategies in patients with obesity, particularly in patients with BMI &gt;40 kg/m<sup>2</sup> or high-risk populations such as intracranial hemorrhage. Further studies are required to evaluate weight metrics and clinical outcomes in patients with obesity, especially in patients with BMI &gt;40 kg/m<sup>2</sup>.</p></div>
<div class="block doe drugH1Div" id="F5541714"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F5541712"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">Octaplex [Canadian product]: Adolescents ≥17 years: Refer to adult dosing.</p></div>
<div class="block dorp drugH1Div" id="F51159547"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51159548"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F5541171"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Asthenia (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arteriovenous fistula site complication (clot: 1%), atrial fibrillation (4%), deep vein thrombosis (1%), heart failure (≤3%), hypotension (7%; including hemorrhagic shock, orthostatic hypotension), tachycardia (5%), thrombosis (microthrombosis of toes: 1%), venous thrombosis (calf: 1%; radial vein: 1%), unstable angina pectoris (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypervolemia (≤3%), hypokalemia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (3%), diarrhea (2%), nausea and vomiting (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic and oncologic: Anemia (6%), bruise (≤4%), subcutaneous hematoma (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident (1% to 2%), headache (7%), insomnia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (≤4%), hypoxia (≤4%), pleural effusion (4%), pulmonary edema (2%), respiratory distress (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Laceration (≤4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral venous insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (including subdural hemorrhage)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, circulatory shock, hypertension, thromboembolic complications (including acute myocardial infarction, arterial thrombosis, pulmonary embolism)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disseminated intravascular coagulation</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylactic shock, anaphylaxis, angioedema, and nonimmune anaphylaxis)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, paresthesia, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory failure</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F5541101"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;">Balfaxar: Hypersensitivity (ie, anaphylaxis or severe systemic reaction) to prothrombin complex concentrate (PCC) or any component of the formulation; known allergy to heparin or history of heparin-induced thrombocytopenia (product contains heparin), immunoglobulin A (IgA) deficiency, with known antibodies against IgA.</p>
<p style="text-indent:0em;margin-top:2em;">Kcentra, Beriplex P/N [Canadian product]: Hypersensitivity (ie, anaphylaxis or severe systemic reaction) to PCC or any component of the formulation including heparin, factors II, VII, IX, X, protein C and S, antithrombin III and human albumin; disseminated intravascular coagulation (DIC); known heparin-induced thrombocytopenia (product contains heparin).</p>
<p style="text-indent:0em;margin-top:2em;">Octaplex [Canadian product]: Hypersensitivity to PCC or any component of the formulation; heparin-induced thrombocytopenia type II or known allergy to heparin (product contains heparin); non-life-threatening bleeding episodes in individuals with recent myocardial infarction, high risk of thrombosis, or angina pectoris; non-life-threatening bleeding episodes in individuals with untreated disseminated intravascular coagulation (DIC) who can be given fresh frozen plasma (FFP); coagulation disorders due to chronic liver disease or liver transplantation; bleeding associated with hepatic parenchyme disorders, esophageal varices, or major hepatic surgery; immunoglobulin A (IgA) deficiency, with known antibodies against IgA</p></div>
<div class="block war drugH1Div" id="F5541102"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reaction (eg, angioedema, bronchospasm, dyspnea, flushing, hypotension, nausea/vomiting, pulmonary edema, urticaria, tachycardia, tachypnea) may occur; if serious reaction occurs, discontinue administration and begin appropriate treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypercoagulopathy: Administration of prothrombin complex concentrate (PCC) may exacerbate underlying hypercoagulable states in recipients of vitamin K antagonists.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heparin: Formulations may contain heparin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <b>PCC (Human) [(Factors II, VII, IX, X), Protein C, Protein S] contains therapeutic levels of factor VII component</b> and should not be confused with Factor IX complex (Human) [Factors II, IX, X] (Bebulin, Profilnine) which contains low or nontherapeutic levels of factor VII.</p>
<p style="text-indent:-2em;margin-left:4em;">• Coagulation factor deficiency: Hepatic synthesis of the prothrombin complex (Factors II, VII, IX and X) coagulation factors is vitamin K dependent. Severe hepatic dysfunction, inadequate absorption of vitamin K (eg, pancreatic disorders, diarrhea) or vitamin K antagonist therapy or overdose may lead to coagulation factor deficiencies. In patients with an acquired deficiency of the vitamin K dependent coagulation factors, administer PCC only if a rapid correction (eg, emergency surgery, major bleeding) is necessary. If not indicated and caused by Vitamin K antagonist therapy, coagulation factor deficiencies may be managed by reducing or discontinuing therapy of the vitamin K antagonist and/or administration of vitamin K.</p></div>
<div class="block dosfc drugH1Div" id="F25484314"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Potency on the vial label is expressed in terms of the Factor IX nominal strength (500 units or 1,000 units). Consult individual vial labels for exact potency within each vial.</p>
<p style="text-indent:-2em;margin-left:2em;">Balfaxar:</p>
<p style="text-indent:-2em;margin-left:4em;">Total active ingredient composition of 500 unit vial:</p>
<p style="text-indent:-2em;margin-left:6em;">Factor II: 340 to 500 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor VII: 240 to 400 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor IX: 400 to 640 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor X: 300 to 540 units</p>
<p style="text-indent:-2em;margin-left:6em;">Protein C: 320 to 560 units</p>
<p style="text-indent:-2em;margin-left:6em;">Protein S: 240 to 600 units</p>
<p style="text-indent:-2em;margin-left:6em;">Heparin: 80 to 384 units</p>
<p style="text-indent:-2em;margin-left:4em;">Total active ingredient composition of 1,000 unit vial:</p>
<p style="text-indent:-2em;margin-left:6em;">Factor II: 680 to 1,000 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor VII: 480 to 800 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor IX: 800 to 1,280 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor X: 600 to 1,080 units</p>
<p style="text-indent:-2em;margin-left:6em;">Protein C: 640 to 1,120 units</p>
<p style="text-indent:-2em;margin-left:6em;">Protein S: 480 to 1,200 units</p>
<p style="text-indent:-2em;margin-left:6em;">Heparin: 160 to 768 units</p>
<p style="text-indent:-2em;margin-left:2em;">Kcentra, Beriplex P/N [Canadian product]:</p>
<p style="text-indent:-2em;margin-left:4em;">Total active ingredient composition of 500 unit vial:</p>
<p style="text-indent:-2em;margin-left:6em;">Factor II: 380 to 800 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor VII: 200 to 500 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor IX: 400 to 620 units (Kcentra) or 500 units (Beriplex P/N)</p>
<p style="text-indent:-2em;margin-left:6em;">Factor X: 500 to 1,020 units</p>
<p style="text-indent:-2em;margin-left:6em;">Protein C: 420 to 820 units</p>
<p style="text-indent:-2em;margin-left:6em;">Protein S: 240 to 680 units</p>
<p style="text-indent:-2em;margin-left:6em;">Heparin: 8 to 40 units (Kcentra) or up to 40 units (Beriplex P/N)</p>
<p style="text-indent:-2em;margin-left:4em;">Total active ingredient composition of 1,000 unit vial:</p>
<p style="text-indent:-2em;margin-left:6em;">Factor II: 760 to 1,600 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor VII: 400 to 1,000 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor IX: 800 to 1,240 units (Kcentra) or 1,000 units (Beriplex P/N)</p>
<p style="text-indent:-2em;margin-left:6em;">Factor X: 1,000 to 2,040 units</p>
<p style="text-indent:-2em;margin-left:6em;">Protein C: 840 to 1,640 units</p>
<p style="text-indent:-2em;margin-left:6em;">Protein S: 480 to 1,360 units</p>
<p style="text-indent:-2em;margin-left:6em;">Heparin: 16 to 80 units (Kcentra) or up to 80 units (Beriplex P/N)</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Octaplex [Canadian product]: <b>Note:</b> Potency on the vial label is expressed in terms of the Factor IX nominal strength (500 units or 1,000 units). Consult individual vial labels for exact potency within each vial.</p>
<p style="text-indent:-2em;margin-left:4em;">Total active ingredient composition of 500 unit vial:</p>
<p style="text-indent:-2em;margin-left:6em;">Factor II: 280 to 760 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor VII: 180 to 480 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor IX: 500 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor X: 360 to 600 units</p>
<p style="text-indent:-2em;margin-left:6em;">Protein C: 260 to 620 units</p>
<p style="text-indent:-2em;margin-left:6em;">Proteins S: 240 to 640 units</p>
<p style="text-indent:-2em;margin-left:6em;">Heparin: 80 to 310 units</p>
<p style="text-indent:-2em;margin-left:4em;">Total active ingredient composition of 1,000 unit vial:</p>
<p style="text-indent:-2em;margin-left:6em;">Factor II: 560 to 1,520 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor VII: 360 to 960 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor IX: 1,000 units</p>
<p style="text-indent:-2em;margin-left:6em;">Factor X: 720 to 1,200 units</p>
<p style="text-indent:-2em;margin-left:6em;">Protein C: 520 to 1,240 units</p>
<p style="text-indent:-2em;margin-left:6em;">Protein S: 480 to 1,280 units</p>
<p style="text-indent:-2em;margin-left:6em;">Heparin: 160 to 620 units</p></div>
<div class="block foc drugH1Div" id="F20960658"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kcentra: ~500 units, ~1000 units [pyrogen free; contains albumin human, antithrombin iii (human), heparin]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Balfaxar: 500 units (1 ea); 1000 units (1 ea)</p></div>
<div class="block geq drugH1Div" id="F25574219"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F21121600"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Kcentra Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $3.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $3.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Balfaxar Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $3.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $3.78</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868922"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Beriplex P/N: 500 units (1 ea); 1000 units (1 ea) [contains albumin human, heparin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Octaplex: 500 units (1 ea); 1000 units (1 ea) [contains heparin, polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F5541715"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Balfaxar, Kcentra, Beriplex P/N [Canadian product]: IV: Administer at room temperature at a rate of 0.12 mL/kg/minute (~3 <b>units</b>/kg/minute); do <b>not</b> exceed 8.4 mL/minute (~210 <b>units</b>/minute). Do not allow blood to enter into syringe (fibrin clot formation may occur).</p>
<p style="text-indent:-2em;margin-left:2em;">Octaplex [Canadian product]: IV: Administer at a rate of 1 mL/minute initially, followed by 2 to 3 mL/minute. Reduce infusion rate or interrupt infusion if patient’s pulse rate increases significantly.</p></div>
<div class="block admp drugH1Div" id="F52614261"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Octaplex [Canadian product]: Administer at a rate of 1 mL/minute initially, followed by 2 to 3 mL/minute. Reduce infusion rate or interrupt infusion if patient's pulse rate increases significantly. Do not mix with other drugs; if administering through IV line, ideally a new, clean line should be used; if an existing line must be used, flush with NS or D5W.</p></div>
<div class="block use drugH1Div" id="F5541097"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Reversal of vitamin K antagonist in patients with acute major bleeding or need for an urgent surgery/invasive procedure:</b> Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (eg, warfarin) therapy in adult patients with acute major bleeding (Kcentra, Beriplex P/N [Canadian product], Octaplex [Canadian product]) or with a need for an urgent surgery/invasive procedure (Balfaxar, Kcentra, Beriplex P/N [Canadian product], Octaplex [Canadian product]).</p></div>
<div class="block off-label drugH1Div" id="F49096481"><span class="drugH1">Use: Off-Label: Adult</span><p>Life-threatening bleeding associated with direct factor Xa inhibitor or direct thrombin inhibitor; Perioperative coagulopathy; Reversal of oral direct factor Xa inhibitor in patients who require urgent procedure (if andexanet alfa unavailable)</p></div>
<div class="block mst drugH1Div" id="F20996439"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The term “Prothrombin Complex Concentrate” or “PCC” has been used to describe both Factor IX Complex (Human) [Factors II, IX, X] and Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, Protein S]. <b>Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, Protein S] (Balfaxar, Beriplex P/N [Canadian product], Kcentra, Octaplex [Canadian product]) contains therapeutic levels of factor VII component</b> and should not be confused with Factor IX complex (Human) [Factors II, IX, X] (Bebulin, Profilnine) which contains low or nontherapeutic levels of factor VII.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Potency on the vial label is expressed in terms of the factor IX nominal strength (500 units or 1,000 units). Consult individual vial labels for exact potency within each vial. Manufacturer's labeling recommends the exact amount of factor IX units in each vial be used when calculating and preparing the total dose to be administered. However, the Institute for Safe Medication Practices recommends using the nominal strength as described in clinical trials (ISMP 2017).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F49648047"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F49648044"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antifibrinolytic Agents: May enhance the adverse/toxic effect of Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, and Protein S]. Specifically, the risk for thrombosis may be increased.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F5541098"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. This product is derived from purified human plasma.</p></div>
<div class="block brc drugH1Div" id="F20858542"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if prothrombin complex concentrate is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that prothrombin complex concentrate be administered only if clearly needed when treating a breastfeeding patient.</p></div>
<div class="block mop drugH1Div" id="F5541717"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">INR (baseline and at 30 minutes post dose); clinical response during and after treatment; signs of thromboembolism</p></div>
<div class="block pha drugH1Div" id="F5541709"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Prothrombin complex concentrate provides an increase in the levels of the vitamin K-dependent coagulation factors (II, VII, IX, and X) with the addition of protein C and protein S. Coagulation factors II, IX, and X are part of the intrinsic coagulation pathway, while factor VII is part of the extrinsic coagulation pathway. In the <i>extrinsic</i> pathway, damaged blood vessels release endothelial tissue factor (TF) which complexes with factor VII to form TF-factor VIIa. Within the <i>intrinsic</i> pathway, factor IX is converted to IXa. Factor IXa (as well as TF-factor VIIa) converts factor X to factor Xa in the final common pathway of coagulation. Factor Xa activates prothrombin (factor II) into thrombin (IIa) which converts fibrinogen into fibrin resulting in clot formation. Proteins C and S are vitamin K-dependent inhibiting enzymes involved in regulating the coagulation process. Protein S serves as a cofactor for protein C which is converted to activated protein C (APC). APC is a serine protease which inactivates factors Va and VIIIa, limiting thrombotic formation. </p></div>
<div class="block phk drugH1Div" id="F5541197"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Rapid; significant INR decline within 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: INR reversal usually maintained for up to ≥24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub> (Kcentra, Beriplex P/N [Canadian product]): Factor II: 71.4 mL/kg; Factor VII: 45 mL/kg; Factor IX: 114.3 mL/kg; Factor X: 55.5 mL/kg; Protein C: 62.2 mL/kg; Protein S: 78.8 mL/kg. <b>Note:</b> Distribution data for Balfaxar and Octaplex (Canadian product) not reported in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Factor II: 48 to 60 hours; Factor VII: 1.5 to 6 hours; Factor IX: 20 to 24 hours; Factor X: 24 to 48 hours; Protein C: 1.5 to 6 hours; Protein S: 24 to 48 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Half-lives may be significantly reduced in severe hepatocellular damage, DIC, or extended catabolic metabolism.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F24057156"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Beriplex p/n</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Beriplex p/n | Octaplex</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Beriplex p/n | Octaplex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Octaplex 500</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Beriplex | Ocplex</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Octaplex | PPSB human SD/Nano</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Beriplex</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Confidex | Octaplex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Confidex | Octaplex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Beriplex | Octaplex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Beriplex p/n</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Beriplex p/n | Prothrombin complex</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Confidex | Pronativ</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Kcentra</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Beriplex</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Confidex | Octapro</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Confidex | Octaplex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Beriplex | Octaplex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Beriplex p/n | Octaplex</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Coaplex | Octaplex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Beriplex p/n | Octaplex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Confidex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Beriplex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Beriplex | Octaplex</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Octaplex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25545654">
<a name="25545654"></a>American Society of Anesthesiologists (ASA) Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*. <i>Anesthesiology</i>. 2015;122(2):241-275. doi:10.1097/ALN.0000000000000463<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/25545654/pubmed" id="25545654" target="_blank">25545654</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Balfaxar (prothrombin complex concentrate human) [prescribing information]. Paramus, NJ: Octapharma USA Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34523108">
<a name="34523108"></a>Bartoszko J, Callum J, Karkouti K; FIBRES study investigators. The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial.<i> Can J Anaesth</i>. 2021;68(12):1789-1801. doi:10.1007/s12630-021-02100-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/34523108/pubmed" id="34523108" target="_blank">34523108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31732375">
<a name="31732375"></a>Baugh CW, Levine M, Cornutt D, et al. Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel [published online November 13, 2019]. <i>Ann Emerg Med</i>. doi:10.1016/j.annemergmed.2019.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/31732375/pubmed" id="31732375" target="_blank">31732375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Beriplex.1">
<a name="Beriplex.1"></a>Beriplex P/N (prothrombin complex concentrate human) [product monograph]. Ottawa, Ontario, Canada: CSL Behring Canada Inc; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31787372">
<a name="31787372"></a>Bitonti MT, Rumbarger RL, Absher RK, Curran LM. Prospective evaluation of a fixed-dose 4-factor prothrombin complex concentrate protocol for urgent vitamin K antagonist reversal. <i>J Emerg Med</i>. 2020;58(2):324-329. doi:10.1016/j.jemermed.2019.10.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/31787372/pubmed" id="31787372" target="_blank">31787372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26738468">
<a name="26738468"></a>Cappabianca G, Mariscalco G, Biancari F, et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. <i>Crit Care</i>. 2016;20:5. doi:10.1186/s13054-015-1172-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/26738468/pubmed" id="26738468" target="_blank">26738468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11198768">
<a name="11198768"></a>Cartmill M, Dolan G, Byrne JL, et al. Prothrombin Complex Concentrate for Oral Anticoagulant Reversal in Neurosurgical Emergencies. <i>Br J Neurosurg</i>. 2000;14(5):458-461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/11198768/pubmed" id="11198768" target="_blank">11198768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27573206">
<a name="27573206"></a>Connolly SJ, Milling TJ Jr, Eikelboom JW, et al; ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. <i>N Engl J Med</i>. 2016;375(12):1131-1141. doi:10.1056/NEJMoa1607887<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/27573206/pubmed" id="27573206" target="_blank">27573206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30916798">
<a name="30916798"></a>Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum. <i>Am J Hematol</i>. 2019;94(6):697-709. doi:10.1002/ajh.25475<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/30916798/pubmed" id="30916798" target="_blank">30916798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016;24(1):6-46. doi:10.1007/s12028-015-0222-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31707622">
<a name="31707622"></a>Fuh L, Goldstein JN, Hayes BD. Initiation of a fixed-dose four-factor prothrombin complex concentrate protocol. <i>J Thromb Thrombolysis</i>. 2020;50(1):217-220. doi:10.1007/s11239-019-01984-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/31707622/pubmed" id="31707622" target="_blank">31707622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31864879">
<a name="31864879"></a>Gilbert BW, Morton L, Huffman JB, et al. Modified version of the American College of Cardiology's recommendation for low-dose prothrombin complex concentrate is effective for warfarin reversal. <i>Am J Emerg Med</i>. 2020;38(4):806-809. doi:10.1016/j.ajem.2019.12.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/31864879/pubmed" id="31864879" target="_blank">31864879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33285008">
<a name="33285008"></a>Green L, Roberts N, Cooper J, et al. Prothrombin complex concentrate vs. fresh frozen plasma in adult patients undergoing heart surgery - a pilot randomised controlled trial (PROPHESY trial). <i>Anaesthesia</i>. 2021;76(7):892-901. doi:10.1111/anae.15327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/33285008/pubmed" id="33285008" target="_blank">33285008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35579034">
<a name="35579034"></a>Greenberg SM, Ziai WC, Cordonnier C, et al; American Heart Association/American Stroke Association. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2022;53(7):e282-e361. doi:10.1161/STR.0000000000000407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/35579034/pubmed" id="35579034" target="_blank">35579034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36408876">
<a name="36408876"></a>Hayes K, Fernando MC, Jordan V. Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding. <i>Cochrane Database Syst Rev.</i> 2022;11(11):CD013551. doi:10.1002/14651858.CD013551.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/36408876/pubmed" id="36408876" target="_blank">36408876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324838">
<a name="26324838"></a>Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i>. 2015;17(10):1467-1507. doi:10.1093/europace/euv309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/26324838/pubmed" id="26324838" target="_blank">26324838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practices (ISMP). ISMP medication safety self assessment for antithrombotic therapy. https://www.ismp.org/assessments/antithrombotic-therapy. Published March 1, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.2">
<a name="ISMP.2"></a>Institute for Safe Medication Practice (ISMP). Misleading Kcentra Label Leads to Dosage Errors. Acute Care ISMP Medication Safety Alert, July 31, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27875491">
<a name="27875491"></a>Joseph B, Khalil M, Harrison C, et al. Assessing the efficacy of prothrombin complex concentrate in multiply injured patients with high-energy pelvic and extremity fractures. <i>J Orthop Trauma</i>. 2016;30(12):653-658. doi:10.1097/BOT.0000000000000665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/27875491/pubmed" id="27875491" target="_blank">27875491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25886249">
<a name="25886249"></a>Joseph B, Pandit V, Khalil M, et al. Use of prothrombin complex concentrate as an adjunct to fresh frozen plasma shortens time to craniotomy in traumatic brain injury patients. <i>Neurosurgery</i>. 2015;76(5):601-607; discussion 607. doi:10.1227/NEU.0000000000000685<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/25886249/pubmed" id="25886249" target="_blank">25886249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33792729">
<a name="33792729"></a>Karkouti K, Bartoszko J, Grewal D, et al. Comparison of 4-factor prothrombin complex concentrate with frozen plasma for management of hemorrhage during and after cardiac surgery: a randomized pilot trial. <i>JAMA Netw Open</i>. 2021;4(4):e213936. doi:10.1001/jamanetworkopen.2021.3936<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/33792729/pubmed" id="33792729" target="_blank">33792729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kcentra.1">
<a name="Kcentra.1"></a>Kcentra (prothrombin complex concentrate human) [prescribing information]. Kankakee, IL: CSL Behring; received May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22491734">
<a name="22491734"></a>Khorsand N, Veeger NJ, van Hest RM, Ypma PF, Heidt J, Meijer K. An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies. <i>Haematologica</i>. 2012;97(10):1501-1506. doi:10.3324/haematol.2012.063701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/22491734/pubmed" id="22491734" target="_blank">22491734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24827116">
<a name="24827116"></a>Kirchner C, Dirkmann D, Treckmann JW, et al. Coagulation management with factor concentrates in liver transplantation: a single-center experience. <i>Transfusion</i>. 2014;54(10 Pt 2):2760-2768. doi:10.1111/trf.12707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/24827116/pubmed" id="24827116" target="_blank">24827116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28459785">
<a name="28459785"></a>Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016. <i>Eur J Anaesthesiol.</i> 2017;34(6):332-395. doi:10.1097/EJA.0000000000000630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/28459785/pubmed" id="28459785" target="_blank">28459785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15226091">
<a name="15226091"></a>Lubetsky A, Hoffman R, Zimlichman R, et al. Efficacy and Safety of a Prothrombin Complex Concentrate (Octaplex) for Rapid Reversal of Oral Anticoagulation. <i>Thromb Res.</i> 2004;113(6):371-378.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/15226091/pubmed" id="15226091" target="_blank">15226091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15792674">
<a name="15792674"></a>Makris M. Optimization of the Prothrombin Complex Concentrate Dose for Warfarin Reversal. <i>Thromb Res</i>. 2005;115(6):451-453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/15792674/pubmed" id="15792674" target="_blank">15792674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32118854">
<a name="32118854"></a>Nascimento JCR, Neto EBL, da Silva EL, et al. Analysis of the hemostatic therapy in liver transplantation guided by rotational thromboelastometry or conventional laboratory tests.<i> Eur J Gastroenterol Hepatol</i>. 2020;32(11):1452-1457. doi:10.1097/MEG.0000000000001660<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/32118854/pubmed" id="32118854" target="_blank">32118854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Octaplex.1">
<a name="Octaplex.1"></a>Octaplex (prothrombin complex concentrate human) [product monograph]. Toronto, Ontario, Canada: Octapharma Canada Inc; October 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25822921">
<a name="25822921"></a>Ortmann E, Besser MW, Sharples LD, et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. <i>Anesth Analg.</i> 2015;121(1):26-33. doi:10.1213/ANE.0000000000000689<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/25822921/pubmed" id="25822921" target="_blank">25822921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18208533">
<a name="18208533"></a>Pabinger I, Brenner B, Kalina U, et al. Prothrombin Complex Concentrate (Beriplex® P/N) for Emergency Anticoagulation Reversal: A Prospective Multinational Clinical Trial. <i>J Thromb Haemost</i>. 2008;6(4):622-631.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/18208533/pubmed" id="18208533" target="_blank">18208533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27558534">
<a name="27558534"></a>Pratt Cleary J, Hodge L, Palmer B, Barreiro CJ, Ingemi A. 4-Factor prothrombin complex concentrate (PCC4, Kcentra®) protocol reduces blood requirements for heart transplantation: a novel protocol. <i>Ann Transplant</i>. 2016;21:531-537. doi:10.12659/aot.898496<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/27558534/pubmed" id="27558534" target="_blank">27558534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34870070">
<a name="34870070"></a>Rimsans J, Berger K, Culbreth S, et al. Comparison of 4F-PCC in obese and nonobese patients with life-threatening bleeding or requiring emergent surgery. <i>Res Pract Thromb Haemost</i>. 2021;5(8):e12624. doi:10.1002/rth2.12624<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/34870070/pubmed" id="34870070" target="_blank">34870070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30892733">
<a name="30892733"></a>Schwebach AA, Waybright RA, Johnson TJ. Fixed-dose four-factor prothrombin complex concentrate for vitamin K antagonist reversal: does one dose fit all? <i>Pharmacotherapy</i>. 2019;39(5):599-608. doi:10.1002/phar.2261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/30892733/pubmed" id="30892733" target="_blank">30892733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30460443">
<a name="30460443"></a>Smetana KS, Ziemba R, May CC, Erdman MJ, Van Matre ET, Jones GM. Adjusted versus actual body weight dosing of 4-factor prothrombin complex concentrate in obese patients with warfarin-associated major bleeding. <i>J Thromb Thrombolysis</i>. 2019;47(3):369-374. doi:10.1007/s11239-018-1771-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/30460443/pubmed" id="30460443" target="_blank">30460443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35767271">
<a name="35767271"></a>Smith MM, Schroeder DR, Nelson JA, et al. Prothrombin complex concentrate vs plasma for post-cardiopulmonary bypass coagulopathy and bleeding: a randomized clinical trial. <i>JAMA Surg.</i> 2022;157(9):757-764. doi:10.1001/jamasurg.2022.2235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/35767271/pubmed" id="35767271" target="_blank">35767271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32680646">
<a name="32680646"></a>Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee.<i> J Am Coll Cardiol</i>. 2020;76(5):594-622. doi:10.1016/j.jacc.2020.04.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/32680646/pubmed" id="32680646" target="_blank">32680646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37080658">
<a name="37080658"></a>Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/37080658/pubmed" id="37080658" target="_blank">37080658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29397934">
<a name="29397934"></a>Wu DW, Xia Y, Uelinger J, et al. Impact of prothrombin complex concentrate on blood use, cost, and outcomes in heart transplantation. <i>Ann Thorac Surg</i>. 2018;105(4):1152-1157. doi:10.1016/j.athoracsur.2017.10.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prothrombin-complex-concentrate-4-factor-unactivated-from-human-plasma-drug-information/abstract-text/29397934/pubmed" id="29397934" target="_blank">29397934</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9450 Version 183.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
